Due to the lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.Updates regarding government operating status and resumption of normal operations can be found at http://www.usa.gov.
Notice Number: NOT-NS-13-005
Release Date: December 20, 2012
Estimated Publication Date of Announcement: May 1, 2013
First Estimated Application Due Date: September 16, 2013
Earliest Estimated Award Date: July 1, 2014
Earliest Estimated Start Date: July 1, 2014
National Institute of Neurological Disorders and Stroke (NINDS)
The National Institute of Neurological Disorders and Stroke (NINDS), intends to re-issue a Program Announcement with Special Review Considerations (PAR) to solicit applications for “Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54)”. The goal of this initiative is to provide support for translational research to develop therapeutics for reducing mortality and morbidity caused by acute exposures to chemical threat agents. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. The scope of the research supported within this milestone-driven translational program includes target and candidate identification and characterization, through candidate optimization and demonstration of in vivo efficacy, through Investigational New Drug (IND) submission. See www.ninds.nih.gov/counteract for a description of the CounterACT program.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and competitive research programs.
The FOA is expected to be published in Spring 2013 with an expected receipt date in September 2013.
This FOA will utilize the U54 activity code. Details of the planned FOA are provided below.
This Notice encourages collaborative multidisciplinary investigations, combining expertise in toxicology and drug discovery and development, to discover and develop new or improved therapeutics for treating victims of chemical exposures.
The CounterACT research program will utilize Specialized Center Cooperative Agreements (U54) to support Research Centers of Excellence for up to 5 years of translational research. Each Research Center must establish milestones that include discrete and quantitative goals that create go or no-go decision points in the project. Each Center will include several individual research projects and scientific and administrative cores to create an interdisciplinary and synergistic multifaceted research approach, centered on a central common goal. Chemical threats to be covered include chemical warfare agents (e.g. sarin, VX), Toxic Industrial Chemicals (e.g. phosgene, sulfur dioxide) and others. Please contact the NIH Program Director below to discuss chemical threats to be covered. The NIH intends to commit approximately $3-4 million per year in Fiscal Years 2014, 2015, and 2016 to fund new and/or competing renewal U54 awards. Since the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend on the number, quality, duration, and costs of the applications received. It is anticipated that several other NIH Institutes, including the National Eye Institute (NEI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), and the National Institute of General Medical Sciences (NIGMS), may also participate in this funding opportunity announcement.
APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.
Please direct all inquiries to:
David A. Jett, Ph.D.
Program Director, NIH CounterACT Research
National Institutes of Health, NINDS
6001 Executive Blvd.
NSC, Room 2177, MSC 9527
Bethesda, MD 20892-9527
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
NIH . . . Turning Discovery Into Health
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.